PRESS RELEASES

EPIVAX PROGRESSES ON A VACCINE TO ADDRESS SARS-COV-2 VARIANTS

November 30, 2021

EpiVax Therapeutics, Inc. is committed to move a novel T cell epitope vaccine  (EPV-CoV-19) into the clinic in 2022.